<!-- modules/module46.html -->
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Angiotensin-converting enzyme inhibitors - KMTC Pharmacology Notes</title>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Angiotensin-converting enzyme inhibitors - KMTC Pharmacology Notes</title>
    <meta name="description" content="This module covers Angiotensin-converting enzyme inhibitors (ACEIs) like Captopril, detailing their uses and nursing considerations.">
</head>
<body>
    <article class="learning-module" data-module="46">
        <nav class="module-nav">
            <div class="nav-links">
              <a href="../index.html">Home</a>
              <a href="module45.html">Previous</a>
              <a href="module47.html">Next</a>
            </div>
            <div class="module-progress">
              <span>Module 46 of 89</span>
            </div>
          </nav>

        <header class="module-header">
            <h1>Angiotensin-converting enzyme inhibitors</h1>
            <section class="module-objectives">
                <h2>üéØ Learning Objectives</h2>
                <ul>
                    <li>Explain the renin-angiotensin-aldosterone system (RAAS) and its role in blood pressure regulation.</li>
                    <li>Describe the mechanism of action of Angiotensin-Converting Enzyme Inhibitors (ACEIs) in lowering blood pressure.</li>
                    <li>Identify the therapeutic uses of ACEIs, particularly Captopril.</li>
                    <li>Discuss the contraindications, side effects, and drug interactions associated with ACEIs.</li>
                    <li>Detail the nursing considerations for patients receiving ACEIs, including monitoring and patient education.</li>
                </ul>
            </section>
        </header>

        <main class="module-content">
            <section class="content-section">
                <h2>üìö Angiotensin-converting enzyme inhibitors</h2>
                <div class="content-block">
                    <p><strong>Angiotensin-converting enzyme inhibitors (ACEIs)</strong> are a class of antihypertensive drugs that act by inhibiting the renin-angiotensin-aldosterone system (RAAS). The RAAS is a critical hormonal system that regulates blood pressure and fluid balance in the body. Understanding the RAAS is key to understanding how ACEIs work.</p>
                    <section class="content-section">
                        <h3>The Renin-Angiotensin-Aldosterone System (RAAS):</h3>
                        <div class="content-block">
                            <ul>
                                <li>Hormonal Cascade: The RAAS is a complex hormonal cascade that begins with the release of renin, an enzyme, from the kidneys in response to decreased blood pressure, decreased sodium delivery to the distal tubules, or sympathetic nervous system stimulation.</li>
                                <li>Angiotensin II Formation: Renin converts angiotensinogen (produced by the liver) to angiotensin I, which is then converted to angiotensin II by angiotensin-converting enzyme (ACE), primarily in the lungs.</li>
                                <li>Actions of Angiotensin II: Angiotensin II is a potent vasoconstrictor and plays a central role in RAAS effects:
                                    <ul>
                                        <li>Vasoconstriction: Causes constriction of blood vessels, increasing peripheral vascular resistance and blood pressure.</li>
                                        <li>Aldosterone Release: Stimulates the adrenal cortex to release aldosterone, a hormone that acts on the kidneys to increase sodium and water reabsorption, expanding blood volume and further increasing blood pressure.</li>
                                        <li>Sodium and Water Retention: Promotes sodium and water retention by the kidneys, contributing to increased blood volume and blood pressure.</li>
                                    </ul>
                                </li>
                            </ul>
                        </div>
                    </section>
                     <figure class="content-image">
                        <img src="../assets/images/KMTC_Pharmacology.jpg"
                             alt="Diagram illustrating the Renin-Angiotensin-Aldosterone System (RAAS), showing the cascade from Renin release to Angiotensin II formation and its effects on vasoconstriction and aldosterone release, ultimately increasing blood pressure."
                             width="600" height="300">
                        <figcaption>The Renin-Angiotensin-Aldosterone System (RAAS)</figcaption>
                    </figure>
                </div>
            </section>

            <section class="content-section">
                <h2>üìö Action of ACE Inhibitors</h2>
                <div class="content-block">
                    <p><strong>ACE Inhibitors</strong> lower blood pressure by blocking the action of angiotensin-converting enzyme (ACE). Their mechanism of action involves:</p>
                    <ul>
                        <li>Inhibition of Angiotensin-Converting Enzyme (ACE): ACE inhibitors block the enzyme ACE, preventing the conversion of angiotensin I to angiotensin II.</li>
                        <li>Reduced Angiotensin II Levels: This inhibition leads to decreased levels of angiotensin II in the blood, resulting in several effects that lower blood pressure:
                            <ul>
                                <li>Vasodilation: Reduced angiotensin II levels cause vasodilation (relaxation of blood vessels), decreasing peripheral vascular resistance and lowering blood pressure.</li>
                                <li>Reduced Aldosterone Secretion: Decreased angiotensin II leads to reduced aldosterone release from the adrenal glands. Lower aldosterone levels decrease sodium and water retention by the kidneys, reducing blood volume and blood pressure.</li>
                                <li>No Increase in Heart Rate or Contractility: Unlike some other antihypertensives, ACE inhibitors typically do not cause significant changes in heart rate or cardiac contractility directly.</li>
                            </ul>
                        </li>
                        <li>Additional Effects:
                            <ul>
                                <li>Reduced Aldosterone Secretion: Leads to decreased aldosterone secretion, which reduces sodium and water retention and increases potassium retention, which can be a concern in patients with renal impairment or those taking potassium-sparing diuretics.</li>
                                <li>No increase in heart rate or cardiac output</li>
                            </ul>
                        </li>
                    </ul>
                </div>
            </section>

            <section class="content-section">
                <h2>üìö 1. Captopril: An ACE Inhibitor Example (Capoten)</h2>
                <div class="content-block">
                    <p><strong>Captopril (Capoten)</strong> is a prototype ACE inhibitor, notable for being one of the first ACE inhibitors developed and for its relatively short duration of action. Key features include:</p>
                    <ul>
                        <li>Trade name: Capoten, nhabace.</li>
                        <li>Class: Antihypertensive, Angiotensin Converting Enzyme Inhibitor.</li>
                        <li>Action: Captopril is a highly specific competitive inhibitor of angiotensin I-converting enzyme (ACE). It:
                            <ul>
                                <li>Inhibits ACE: Prevents the conversion of angiotensin I to angiotensin II.</li>
                                <li>Reduces Peripheral Resistance: Decreases peripheral arterial resistance by reducing angiotensin II-mediated vasoconstriction.</li>
                                <li>Decreases Aldosterone Secretion: Reduces aldosterone secretion, leading to decreased sodium and water retention and a mild increase in serum potassium levels.</li>
                            </ul>
                        </li>
                        <li>Indications: Primarily used for:
                            <ul>
                                <li>Hypertension: Effective in managing essential hypertension.</li>
                                <li>Congestive Heart Failure (CHF): Used in combination with diuretics and digitalis to manage CHF, particularly to reduce afterload and improve cardiac output.</li>
                            </ul>
                        </li>
                        <li>Contraindication:
                            <ul>
                                <li>Hypersensitivity to captopril or other ACE inhibitors.</li>
                                <li>Renovascular disease: May worsen renal function in patients with bilateral renal artery stenosis.</li>
                                <li>Pregnancy: Contraindicated in pregnancy, especially in the second and third trimesters, due to risk of fetal and neonatal morbidity and mortality.</li>
                            </ul>
                        </li>
                        <li>Side effects: Common side effects include:
                            <ul>
                                <li>Skin rash</li>
                                <li>Loss of taste (dysgeusia), often transient and reversible.</li>
                                <li>Neutropenia (decreased neutrophils), rare but serious.</li>
                                <li>Nausea, vomiting, diarrhea.</li>
                                <li>Hypotension, particularly orthostatic hypotension.</li>
                                <li>Proteinuria (protein in urine), especially in patients with pre-existing renal disease.</li>
                                <li>Renal failure (in susceptible individuals).</li>
                                <li>Hyperkalemia (elevated serum potassium), due to reduced aldosterone.</li>
                            </ul>
                        </li>
                        <li>Dosage: Available in tablets:
                            <ul>
                                <li>Tablets: Typically starting at 12.5 mg two to three times daily.</li>
                                <li>Dosage Adjustment: If response is inadequate after 1-2 weeks, the dose may be gradually increased to 25 mg two to three times per day, and further as needed, up to a maximum daily dose.</li>
                            </ul>
                        </li>
                    </ul>
                </div>
            </section>

            <section class="practice-activity">
                <h2>‚úçÔ∏è Practice Exercise</h2>
                <div class="activity-content">
                    <p><strong>Question:</strong> Explain how ACE inhibitors like Captopril lower blood pressure by acting on the Renin-Angiotensin-Aldosterone System (RAAS). What are the key steps in the RAAS pathway that are affected by ACE inhibitors?</p>
                    <details class="solution">
                        <summary>View Solution</summary>
                        <div class="solution-content">
                            <p><strong>ACE Inhibitors and the Renin-Angiotensin-Aldosterone System (RAAS):</strong> ACE inhibitors, such as Captopril, effectively lower blood pressure by disrupting the RAAS pathway. The key steps in the RAAS pathway that are targeted by ACE inhibitors are:</p>
                            <ol>
                                <li>Renin Release: The RAAS cascade begins with the release of renin from the kidneys in response to decreased blood pressure, reduced sodium levels in the distal tubules, or sympathetic nervous system activation.</li>
                                <li>Angiotensin I Conversion: Renin acts on angiotensinogen (a protein produced by the liver) to convert it into angiotensin I. Angiotensin I, however, has minimal direct effect on blood pressure.</li>
                                <li><strong>Blockade of Angiotensin-Converting Enzyme (ACE):</strong> This is where ACE inhibitors like Captopril exert their primary action. ACE is an enzyme that catalyzes the conversion of angiotensin I to angiotensin II. By inhibiting ACE, Captopril prevents this conversion, thus reducing the production of angiotensin II.</li>
                                <li>Reduced Angiotensin II Effects: Angiotensin II is a potent hormone with several effects that increase blood pressure. By reducing angiotensin II levels, ACE inhibitors counteract these effects:
                                    <ul>
                                        <li>Vasodilation: Decreased angiotensin II leads to vasodilation of blood vessels, reducing peripheral vascular resistance and lowering blood pressure.</li>
                                        <li>Decreased Aldosterone Release: Angiotensin II normally stimulates the adrenal cortex to release aldosterone. By reducing angiotensin II, ACE inhibitors lower aldosterone levels. Aldosterone promotes sodium and water retention in the kidneys, so reduced aldosterone leads to increased sodium and water excretion, reducing blood volume and blood pressure.</li>
                                    </ul>
                                </li>
                            </ul>
                            <p><strong>In Summary:</strong> ACE inhibitors like Captopril lower blood pressure by blocking the enzyme ACE, which is critical for the conversion of angiotensin I to angiotensin II. This action decreases angiotensin II levels, leading to vasodilation and reduced aldosterone secretion, ultimately lowering blood pressure. By interrupting the RAAS at the ACE step, these drugs effectively manage hypertension and reduce cardiac workload.</p>
                        </div>
                    </details>
                </div>
            </section>
        </main>

        <footer class="module-footer">
            <section class="key-takeaways">
                <h2>üìö Key Takeaways</h2>
                <ul>
                    <li>ACE inhibitors like Captopril lower blood pressure by inhibiting angiotensin-converting enzyme, reducing Angiotensin II and aldosterone levels.</li>
                    <li>Captopril is used for hypertension and CHF; side effects include cough, hypotension, hyperkalemia, and renal issues. Contraindicated in pregnancy and renovascular disease.</li>
                    <li>Nursing considerations for ACE inhibitors include monitoring blood pressure, renal function, potassium levels, and educating patients about side effects and the importance of adherence.</li>
                </ul>
            </section>

            <section class="knowledge-check">
                <h2>‚ö° Knowledge Check</h2>
                <div class="quiz-content">
                    <ol>
                        <li>ACE inhibitors primarily lower blood pressure by:
                            <br> a) Increasing heart rate <br> b) Blocking angiotensin II production <br> c) Promoting sodium retention</li>
                        <li>A common side effect of Captopril is:
                            <br> a) Hyperkalemia <br> b) Hypokalemia <br> c) Bradycardia</li>
                        <li>ACE inhibitors are contraindicated in which condition?
                            <br> a) Asthma <br> b) Pregnancy <br> c) Diabetes insipidus</li>
                    </ol>
                </div>
            </section>
        </footer>
    </article>
</body>
</html>